{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:22:07Z","timestamp":1791836527377,"version":"4.3.4"},"reference-count":87,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Hepatitis B virus (HBV) represents a significant global health challenge, affecting over 254 million individuals and contributing to 1.1 million deaths from liver-related complications in 2022. The World Health Organization has set ambitious targets to reduce HBV infections and mortality by 2030. However, only a small proportion (13%) of infected individuals receives timely diagnosis and treatment. HBV elimination efforts necessitate substantial improvements in HBV diagnosis, particularly in identifying early-stage infections, occult HBV infections (OBI), and breakthrough cases. The hepatitis B surface antigen (HBsAg) is a key biomarker in HBV diagnosis, serving as a reliable indicator of infection status and treatment response. Conventional HBsAg assays, with a lower limit of detection (LoD) between 0.03 and 250 IU\/mL, often fail to detect OBI and HBV reactivation. In contrast, ultrasensitive HBsAg assays, with an LoD as low as 0.005 IU\/mL, can improve the identification of low concentration levels of HBsAg, facilitating earlier diagnosis, monitoring of therapeutic response, and assessment for functional cure. Research confirms the superiority of ultrasensitive assays in detecting HBV in cases missed by conventional assays, detecting NAT-yield samples, and enabling earlier detection of HBV reactivation. This review examines the challenges in HBV diagnostics and the clinical utility of ultrasensitive HBsAg assays in improving progress toward global HBV elimination.<\/jats:p>","DOI":"10.3390\/diagnostics15212744","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:50:19Z","timestamp":1761785419000},"page":"2744","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advancing HBV Diagnostics: The Role of Ultrasensitive HBsAg Testing"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1230-8044","authenticated-orcid":false,"given":"Hussain","family":"Ali","sequence":"first","affiliation":[{"name":"Abbott Diagnostics, Abbott Park, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Buenning","sequence":"additional","affiliation":[{"name":"Abbott Diagnostics, Abbott Park, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Daghfal","sequence":"additional","affiliation":[{"name":"Abbott Diagnostics, Abbott Park, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025, January 04). Hepatitis B. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_2","unstructured":"World Health Organization (2025, January 04). Elimination of Hepatitis by 2030. Available online: https:\/\/www.who.int\/health-topics\/hepatitis\/elimination-of-hepatitis-by-2030#tab=tab_1."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1055\/s-0043-1768633","article-title":"Performance evaluation of an improved HBsAg assay (HBsAg NEXT) for the detection of HBsAg levels","volume":"15","author":"Gupta","year":"2023","journal-title":"J. Lab. Physicians"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100531","DOI":"10.1016\/j.jhepr.2022.100531","article-title":"Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey","volume":"4","author":"Kondili","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: Current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Al-Busafi, S.A., and Alwassief, A. (2024). Global perspectives on the hepatitis B vaccination: Challenges, achievements, and the road to elimination by 2030. Vaccines, 12.","DOI":"10.20944\/preprints202402.0493.v1"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Vachon, A., and Osiowy, C. (2021). Novel biomarkers of hepatitis B virus and their use in chronic hepatitis B patient management. Viruses, 13.","DOI":"10.3390\/v13060951"},{"key":"ref_8","unstructured":"European Association for the Study of the Liver (2025). EASL Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J. Hepatol., 83, 502\u2013583."},{"key":"ref_9","unstructured":"Centers for Disease Control and Prevention (2025, October 22). Hepatitis B Surveillance Guidance, Available online: https:\/\/www.cdc.gov\/hepatitis\/php\/surveillance-guidance\/hepatitis-b.html#:~:text=A%20person%20with%20a%20positive,the%20presence%20of%20HBV%20DNA."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105378","DOI":"10.1016\/j.jcv.2023.105378","article-title":"Versatile performance edges of HBsAg Next assay in diagnosis and therapeutic monitoring of HBV infection","volume":"160","author":"Steve","year":"2023","journal-title":"J. Clin. Virol."},{"key":"ref_11","unstructured":"WHO Guidelines on Hepatitis B and C Testing (2025, October 22). Geneva: World Health Organization; 2017 February, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK442276\/table\/ch7.t1\/."},{"key":"ref_12","unstructured":"(2025, October 22). Centers for Disease Control and Prevention. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations\u2014United States, Available online: https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/rr\/rr7201a1.htm?s_cid=rr7201a1_w."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Moini, M., and Fung, S. (2022). HBsAg loss as a treatment endpoint for chronic HBV infection: HBV cure. Viruses, 14.","DOI":"10.3390\/v14040657"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104507","DOI":"10.1016\/j.jcv.2020.104507","article-title":"The contribution of more sensitive hepatitis B surface antigen assays to detecting and monitoring hepatitis B infection","volume":"129","author":"Pronier","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1128\/CMR.00009-07","article-title":"Molecular testing in the diagnosis and management of chronic hepatitis B","volume":"20","author":"Valsamakis","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_16","unstructured":"Polaris Observatory Collaborators (2022). Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study. Lancet Gastroenterol. Hepatol., 7, 396\u2013415."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Spearman, C.W., Andersson, M.I., Bright, B., Davwar, P.M., Desalegn, H., Guingane, A.N., Johannessen, A., Kabagambe, K., Lemoine, M., and Matthews, P.C. (2023). Hepatitis B in Africa Collaborative Network (HEPSANET). A new approach to prevent, diagnose, and treat hepatitis B in Africa. BMC Glob. Public Health, 1.","DOI":"10.1186\/s44263-023-00026-1"},{"key":"ref_18","unstructured":"Centers for Disease Control and Prevention (2025, August 22). Clinical Testing and Diagnosis for Hepatitis B, Available online: https:\/\/www.cdc.gov\/hepatitis-b\/hcp\/diagnosis-testing\/index.html."},{"key":"ref_19","unstructured":"World Health Organization (2025, October 22). Training Workshop on Screening, Diagnosis and Treatment of Hepatitis B and C. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/searo\/hiv-hepatitis\/training-modules\/08-hbv-serological-markers.pdf?sfvrsn=b4ca38a4_2."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcv.2019.08.001","article-title":"Improved detection of early acute, late acute, and occult hepatitis B infections by an increased sensitivity HBsAg assay","volume":"118","author":"Kuhns","year":"2019","journal-title":"J. Clin. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Update of the statements on biology and clinical impact of occult hepatitis B virus infection","volume":"71","author":"Raimondo","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-0039-1678728","article-title":"Current knowledge of occult hepatitis B infection and clinical implications","volume":"39","author":"Yip","year":"2019","journal-title":"Semin. Liver Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11901-014-0238-2","article-title":"Immunosuppression in patients with chronic hepatitis B","volume":"13","author":"Seetharam","year":"2014","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s10096-011-1240-z","article-title":"The underlying mechanisms for the \u201csimultaneous HBsAg and anti-HBs serological profile\u201d","volume":"30","year":"2011","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wang, C., Xue, R., Wang, X., Xiao, L., and Xian, J. (2023). High-sensitivity HBV DNA test for the diagnosis of occult HBV infection: Commonly used but not reliable. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1186877"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Yan, Y., Sun, H., Chang, L., Ji, H., Jiang, X., Song, S., Xiao, Y., Feng, K., Nuermaimaiti, A., and Lu, Z. (2022). Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.1063616"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Song, S., Su, Q., Yan, Y., Ji, H., Sun, H., Feng, K., Nuermaimaiti, A., Halemubieke, S., Mei, L., and Liu, X. (2025). Identification and characteristics of mutations promoting occult HBV infection by ultrasensitive HBsAg assay. J. Clin. Microbiol., 63.","DOI":"10.1128\/jcm.02071-24"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.cgh.2022.02.027","article-title":"Role of hepatitis B surface antibodies in risk for hepatitis B virus reactivation during anti-tumor necrosis factor therapy","volume":"21","author":"Poola","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2217\/fvl-2021-0275","article-title":"Hepatitis B virus reactivation: Overview and management","volume":"16","author":"Huang","year":"2021","journal-title":"Future Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5009\/gnl210551","article-title":"Risk of hepatitis B virus (HBV) reactivation in HBsAg-negative, anti-HBc-negative patients receiving rituximab for autoimmune diseases in HBV endemic areas","volume":"17","author":"Lan","year":"2023","journal-title":"Gut Liver"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2009.05.001","article-title":"Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Hammond","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B virus reactivation: Risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.cgh.2021.07.036","article-title":"Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update","volume":"20","author":"Martin","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: From discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Degasperi, E., Anolli, M.P., and Lampertico, P. (2022). Towards a functional cure for hepatitis B virus: A 2022 update on new antiviral strategies. Viruses, 14.","DOI":"10.3390\/v14112404"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"Hepatitis B surface antigen levels: Association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol. Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.cgh.2020.04.091","article-title":"Should treatment indications for chronic hepatitis B be expanded?","volume":"19","author":"Jeng","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cld.2019.04.002","article-title":"Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials","volume":"23","author":"Likhitsup","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kumar, M., Pahuja, S., Khare, P., and Kumar, A. (2023). Current challenges and future perspectives of diagnosis of hepatitis B virus. Diagnostics, 13.","DOI":"10.3390\/diagnostics13030368"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1128\/JCM.00324-13","article-title":"Highly sensitive detection of hepatitis B virus surface antigen by use of a semiautomated immune complex transfer chemiluminescence enzyme immunoassay","volume":"51","author":"Takeda","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jceh.2016.07.002","article-title":"Clinical significance of quantitative HBsAg titres and its correlation with HBV DNA levels in the natural history of hepatitis B virus infection","volume":"6","author":"Karra","year":"2016","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Sickinger, E., Braun, H.B., Meyer, T., Schmid, K., Daghfal, D., Oer, M., and Schultess, J. (2020). Performance characteristics of the high sensitivity Alinity i & ARCHITECT HBsAg Next Qualitative\/Confirmatory assays. Diagn. Microbiol. Infect. Dis., 97.","DOI":"10.1016\/j.diagmicrobio.2020.115033"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"105524","DOI":"10.1016\/j.jcv.2023.105524","article-title":"ARCHITECT HBsAg Next assay is positioned better to resolve and refine challenging weak reactive clinical samples","volume":"166","author":"Prakash","year":"2023","journal-title":"J. Clin. Virol."},{"key":"ref_50","unstructured":"World Health Organization (2025, October 22). Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240090903."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"101764","DOI":"10.1016\/j.aohep.2024.101764","article-title":"Clinical usefulness of an ultra-high-sensitivity hepatitis B surface antigen assay to determine the cessation of treatment for HBV reactivation","volume":"30","author":"Suzuki","year":"2025","journal-title":"Ann. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Abu, N., Mohd Bakhori, N., and Shueb, R.H. (2023). Lateral flow assay for hepatitis B detection: A review of current and new assays. Micromachines, 14.","DOI":"10.3390\/mi14061239"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00216-020-03055-z","article-title":"Upconverting nanoparticle reporter-based highly sensitive rapid lateral flow immunoassay for hepatitis B virus surface antigen","volume":"413","author":"Martiskainen","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Amini, A., Varsaneux, O., Kelly, H., Tang, W., Chen, W., Boeras, D.I., Falconer, J., Tucker, J.D., Chou, R., and Ishizaki, A. (2017). Diagnostic accuracy of tests to detect hepatitis B surface antigen: A systematic review of the literature and meta-analysis. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2772-3"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3000605251315913","DOI":"10.1177\/03000605251315913","article-title":"An overview of ELISA: A review and update on best laboratory practices for quantifying peptides and proteins in biological fluids","volume":"53","author":"Aydin","year":"2025","journal-title":"J. Int. Med. Res."},{"key":"ref_56","first-page":"323","article-title":"An automated high-throughput screening enzyme linked immunosorbent assay for Johne\u2019s disease antibodies in bovine serum","volume":"11","author":"Wu","year":"2006","journal-title":"SLAS Technol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13317-017-0097-2","article-title":"Chemiluminescent immunoassay technology: What does it change in autoantibody detection?","volume":"8","author":"Cinquanta","year":"2017","journal-title":"Auto. Immun. Highlights"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Nicolai, E., Sarubbi, S., Pelagalli, M., Basile, V., Terrinoni, A., Minieri, M., Cennamo, O., Grelli, S., Bernardini, S., and Pieri, M. (2023). Performance evaluation of the new chemiluminescence immunoassay CL-1200i for HBV, HIV panels. Diseases, 11.","DOI":"10.3390\/diseases11020083"},{"key":"ref_59","unstructured":"Food and Drug Administration (2025, October 22). ARCHITECT HBsAg Next Qualitative Reagent IFU, Available online: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf21\/P210003C.pdf#:~:text=mIU%2FmL%20LoBa%201,analyte%20samples.%20b."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Wong, D.K., Chen, C., Mak, L.Y., Fung, J., Seto, W.K., and Yuen, M.F. (2022). Detection of the hepatitis B surface antigen in patients with occult hepatitis B by use of an assay with enhanced sensitivity. J. Clin. Microbiol., 60.","DOI":"10.1128\/jcm.02204-21"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcv.2018.05.009","article-title":"An ultra-sensitive Abbott ARCHITECT(\u00ae) assay for the detection of hepatitis B virus surface antigen (HBsAg)","volume":"105","author":"Lou","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jiac.2023.09.007","article-title":"Efficient implementation of hepatitis B surface antigen confirmatory neutralization tests","volume":"30","author":"Yonezawa","year":"2024","journal-title":"J. Infect. Chemother."},{"key":"ref_63","first-page":"9928098","article-title":"An interesting case of isolated false-reactive hepatitis B surface antigen","volume":"2021","author":"Costa","year":"2021","journal-title":"Case Rep. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2021.04.051","article-title":"Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load","volume":"75","author":"Meier","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Kuhns, M.C., Holzmayer, V., Anderson, M., McNamara, A.L., Sauleda, S., Mbanya, D., Duong, P.T., Dung, N.T.T., and Cloherty, G.A. (2021). Molecular and serological characterization of hepatitis B virus (HBV)-Positive samples with very low or undetectable levels of HBV surface antigen. Viruses, 13.","DOI":"10.3390\/v13102053"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12985-019-1154-4","article-title":"Molecular and serological characterization of hepatitis B vaccine breakthrough infections in serial samples from two plasma donors","volume":"16","author":"Kuhns","year":"2019","journal-title":"Virol. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"105707","DOI":"10.1016\/j.jcv.2024.105707","article-title":"Does the ultrasensitive HBsAg Next assay enhance Hepatitis B diagnosis? An evaluation of analytical performances","volume":"174","author":"Bourdin","year":"2024","journal-title":"J. Clin. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00535-016-1244-7","article-title":"Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody","volume":"52","author":"Matsumoto","year":"2016","journal-title":"J. Gastroenterol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multicenter, multiethnic cohort (RETRACT-B Study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.3748\/wjg.v20.i24.7686","article-title":"Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues","volume":"20","author":"Chen","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"Stein","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jhep.2020.03.009","article-title":"Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma","volume":"73","author":"Kusumoto","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/hep4.1767","article-title":"Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4254\/wjh.v8.i8.385","article-title":"Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations","volume":"8","author":"Bessone","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/liv.12055","article-title":"Management of HBV in immunocompromised patients","volume":"33","author":"Pol","year":"2013","journal-title":"Liver Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B virus reactivation in cancer patients with positive hepatitis B surface antigen undergoing PD-1 inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_77","unstructured":"Kuhns, M.C., Holzmayer, V., McNamara, A.L., Rodgers, M.A., Olivo, A.C., Harris, B., Vallari, A., Oliveras, S.S., Kaptue, L., and Mbanya, D. (2019, January 8\u201312). Molecular and Serological Characterization of Hepatitis B Early Acute and Occult Specimens Incrementally Detected by a New Increased Sensitivity HBsAg Assay (663). Proceedings of the AASLD The Liver Meeting 2019, Boston, MA, USA."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(24)00471-9","article-title":"OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: End of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)","volume":"80","author":"Hou","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_79","unstructured":"Centers for Disease Control and Prevention (2025, August 22). Success Story: Costs and Effectiveness of Hepatitis B Screening and Vaccination, Available online: https:\/\/www.cdc.gov\/neema\/php\/successstories\/cost-effectiveness-of-hepatitis-b-screening-vaccination.html."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/HEP.0000000000000430","article-title":"Pathway to global elimination of hepatitis B: HBV cure is just the first step","volume":"78","author":"Howell","year":"2023","journal-title":"Hepatology"},{"key":"ref_81","unstructured":"(2025, August 22). U.S. Food & Drug Administration, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-testing-blood-donations-hepatitis-b-surface-antigen."},{"key":"ref_82","unstructured":"(2025, August 22). Association for the Advancement of Blood & Biotherapies. Available online: https:\/\/www.aabb.org\/news-resources\/news\/article\/2025\/07\/16\/regulatory-update--new-fda-draft-guidance-outlines-recommendations-for-testing-blood-donations-for-hbsag."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2144\/btn-2022-0082","article-title":"Modified ARCHITECT(\u00ae) serologic assays enable plasma-level performance from dried blood spot samples","volume":"73","author":"Holzmayer","year":"2022","journal-title":"Biotechniques"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41575-022-00649-z","article-title":"A roadmap for serum biomarkers for hepatitis B virus: Current status and future outlook","volume":"19","author":"Kramvis","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Kikuchi, M., Lindstrom, P., Tejada-Strop, A., Mixson-Hayden, T., Kamili, S., and Sawabe, M. (2022). Dried blood spot is the feasible matrix for detection of some but not all hepatitis B virus markers of infection. BMC Res. Notes, 15.","DOI":"10.1186\/s13104-022-06178-x"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e163175","DOI":"10.1172\/JCI163175","article-title":"Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNA","volume":"132","author":"Ghany","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e161818","DOI":"10.1172\/JCI161818","article-title":"Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment","volume":"132","author":"Grudda","year":"2022","journal-title":"J. Clin. Investig."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/21\/2744\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:20:22Z","timestamp":1761888022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/21\/2744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":87,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["diagnostics15212744"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15212744","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}